<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="27139">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02753426</url>
  </required_header>
  <id_info>
    <org_study_id>15-17569</org_study_id>
    <nct_id>NCT02753426</nct_id>
  </id_info>
  <brief_title>Doxycycline: A Novel Treatment for Cardiorenal Syndrome</brief_title>
  <official_title>Doxycycline: A Novel Treatment for Cardiorenal Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this trial is to evaluate whether subantimicrobial-dose of doxycycline (20mgBID)
      will affect serum and urine biomarkers of fibrosis in patients with pre-dialysis chronic
      kidney disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase I, placebo-controlled, randomized crossover trial to determine the effects
      of 4-week treatment with subantimicrobial-dose doxycycline on serum and urine biomarkers of
      fibrosis in patients with pre-dialysis chronic kidney disease (eGFR&lt;30ml/min/1.73m2).
      Doxycycline is a matrix metalloproteinase inhibitor and is approved for use as an
      anti-fibrotic in the setting of gum and skin disease at low doses (20mgBID). At such a dose,
      serum levels are too low for antimicrobial effect and chronic usage is not thought to lead
      to tetracycline resistance. Investigators hypothesize that doxycycline will ameliorate
      cardiac and renal fibrosis and thus investigators will detect a decrease in fibrotic markers
      during treatment with doxycycline.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Anticipated">August 2017</completion_date>
  <primary_completion_date type="Anticipated">August 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double Blind (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum markers of fibrosis</measure>
    <time_frame>3 months</time_frame>
    <description>Serum collagen type III amino-terminal propeptide (PIIINP), soluble suppression of tumorigenicity 2 (ST2)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Urinary markers of fibrosis</measure>
    <time_frame>3 months</time_frame>
    <description>Urinary PIIINP, Urinary alpha-1 macroglobulin (A1M)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse effects</measure>
    <time_frame>3 months</time_frame>
    <description>Nausea, rash</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Chronic Kidney Disease</condition>
  <condition>Cardiorenal Syndrome</condition>
  <arm_group>
    <arm_group_label>Doxycycline-Placebo</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Doxycycline 20mg capsule for 30 days, 30-day washout, and then placebo capsule for 30 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo-Doxycycline</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Placebo capsule for 30 days, 30-day washout, and then Doxycycline 20mg capsule for 30 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxycycline</intervention_name>
    <description>Doxycycline 20mg capsule by mouth, twice a day for 30 days.</description>
    <arm_group_label>Doxycycline-Placebo</arm_group_label>
    <arm_group_label>Placebo-Doxycycline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (for Doxycycline)</intervention_name>
    <description>Inactive pill manufactured to mimic Doxycycline 20mg. Capsule by mouth, twice a for 30 days.</description>
    <arm_group_label>Doxycycline-Placebo</arm_group_label>
    <arm_group_label>Placebo-Doxycycline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  CKD pre-dialysis (eGFR&lt; 30 ml/min/1.73m2 not on dialysis);

          -  local 415/650/510 area codes;

          -  primary language English or Spanish

        Exclusion Criteria:

          -  eGFR worsening by greater than 5ml/min/1.73 m2 during the last 6 months;

          -  SBP less than 100mmHg or greater than 170 mmHg;

          -  pregnancy;

          -  ejection fraction less than 45%;

          -  NYHA class III or IV HF;

          -  myocardial infarction or hospitalization for HF within 4 months;

          -  liver disease;

          -  moderate or severe chronic obstructive pulmonary disease or pulmonary fibrosis;

          -  current infection;

          -  chemotherapy;

          -  major surgery within last month;

          -  bilateral dialysis access precluding lab draw;

          -  self-reported use of IV drugs or cocaine within the last 6 months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ruth Dubin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ruth Dubin, MD</last_name>
    <email>ruth.dubin@ucsf.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>San Francisco VA Medical Center: Clinical Research Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Zuckerberg San Francisco General Hospital</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <lastchanged_date>April 26, 2016</lastchanged_date>
  <firstreceived_date>April 24, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Cardio-Renal Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Doxycycline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
